ArticleTranslational cancer research2025
scRNA-seq reveals chemotherapy-induced tumor microenvironment changes in pancreatic ductal adenocarcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring.Frontiers in immunology · 2026Review
- Single-Cell Sequencing Unravels Pancreatic Cancer: Novel Technologies Reveal Novel Aspects of Cellular Heterogeneity and Inform Therapeutic Strategies.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Challenges have arisen in finding an effective treatment for pancreatic ductal adenocarcinoma (PDAC). Poor outcomes have fueled ongoing efforts to exploit the tumor microenvironment (TME) in the treatment of PDAC; however, to date, treatment strategies have largely failed. Thus, a comprehensive and deep understanding of the PDAC TME is necessary. The purpose of the present study was to investigate chemotherapy-induced tumor microenvironment changes and to optimize the response to immunotherapy in PDAC. Methods: We analyzed publicly available single-cell RNA sequencing (scRNA-seq) PDAC (with or without standard chemotherapy) data and performed systematic analyses to elucidate novel mechanisms and to determinate the marker expression alteration induced by the chemotherapy. Results: Lysozyme ( Conclusions: We described the characteristics of widely expressed markers in different cell types in PDAC. Chemotherapy disrupted the TME balance, altered tumor antigen presentation, and changed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.